{"id":408386,"date":"2021-01-05T08:03:32","date_gmt":"2021-01-05T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408386"},"modified":"2021-01-05T08:03:32","modified_gmt":"2021-01-05T13:03:32","slug":"biotricity-submitted-510k-u-s-fda-filing-for-biotres","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/","title":{"rendered":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres"},"content":{"rendered":"<h2>\nBiotres is a compact and discreet 3 channel holter solution<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; Biotricity\u00a0Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it\u00a0made\u00a0a 510(k)\u00a0submission to the U.S. Food and Drug Administration (FDA),\u00a0on December 31 2020,\u00a0for\u00a0Biotres.\u00a0The company expects this process to\u00a0take at least 4 months,\u00a0and if the\u00a0Company\u2019s 510(k) application is cleared by\u00a0the FDA\u00a0the Company expects a product launch\u00a0thereafter.\u00a0<\/p>\n<p>As announced previously,\u00a0Biotres\u00a0is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues.\u00a0Biotres\u00a0can work as a Holter, Event Loop, and Extended Holter.<\/p>\n<p>\u201cWe are excited to announce the 510(k) FDA\u00a0submission\u00a0for\u00a0Biotres\u00a0and look forward to building out our\u00a0product offerings further in 2021,\u201d stated\u00a0Waqaas\u00a0Al Siddiq, CEO of Biotricity. \u201cWe believe that\u00a0Biotres\u00a0addresses demand from\u00a0some of our existing customers and a need in the\u00a0holter\u00a0market.\u201d\u00a0<\/p>\n<p>The\u00a0Biotres\u00a0is a\u00a0holter\u00a0product that was developed to address the challenges that exist with current\u00a0holter\u00a0patch products. The\u00a0Biotres\u00a0is designed with the following key features:<\/p>\n<ul type=\"disc\">\n<li>3 Channel Recording \u2013 A wearable\u00a0holter\u00a0patch device that can provide continuous 3 channel recording of ECG (heart) data. All other\u00a0holter\u00a0patch devices are 1 channel or 2 channels.\u00a0\n<\/li>\n<li>Rechargeable Battery\u00a0\u2013 The device can be worn continuously for\u00a048 hours, before needing to be charged for 1 hr., enabling continuous data collection for extended periods of time without any intervention, something not possible with traditional holter patch solutions.\u00a0\n<\/li>\n<li>Wireless Connectivity \u2013 The unique device utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current\u00a0holter\u00a0patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.\u00a0\n<\/li>\n<li>User-Friendly Design \u2013 Easy to understand and comfortable to wear during regular day-to-day activities.\u00a0<\/li>\n<\/ul>\n<p>About\u00a0Biotricity\u00a0Inc.\u00a0<\/p>\n<p>Biotricity\u00a0is\u00a0reforming\u00a0the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust\u00a0Biotricity\u2019s\u00a0standard for preventive &amp; personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.\u00a0<\/p>\n<p>Important Cautions Regarding Forward-Looking Statements\u00a0<br \/>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our\u00a0future plans, strategies, and expectations, are\u00a0generally identifiable\u00a0by use of the words \u201cmay,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cscheduled,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cbelieve,\u201d \u201cintend,\u201d\u00a0\u201cseek,\u201d \u201cproject,\u201d or \u201cgoal\u201d or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of\u00a0Bioflux\u00a0or any of the Company\u2019s other proposed products or services, (ii) a projection of income (including income\/loss), earnings (including earnings\/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company\u2019s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate\u00a0including our ability to obtain required regulatory approvals\u00a0and (v) the assumptions underlying or relating to any statement described in points (i), (ii)\u00a0or\u00a0\u00a0(iii). Such forward-looking statements are not meant to predict or guarantee actual results, performance,\u00a0events\u00a0or circumstances and may not be realized because they are based upon the Company\u2019s current projections, plans,\u00a0objectives, beliefs, expectations, estimates and assumptions and are subject to\u00a0a number of\u00a0risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements\u00a0as a result of\u00a0these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company\u2019s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company\u2019s inability to expand the Company\u2019s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company\u2019s failure to implement the Company\u2019s business plans or strategies. These and other factors are\u00a0identified\u00a0and described in more detail in the Company\u2019s filings with the SEC.\u00a0The Company assumes no obligation to update any forward-looking statements\u00a0in order to\u00a0reflect any event or circumstance that may arise after the date of this release.\u00a0<\/p>\n<p>Contacts:\u00a0<br \/>Media contacts\u00a0<br \/>Donna Loughlin Michaels\u00a0<br \/>LMGPR\u00a0<br \/>408.393.5575\u00a0<br \/>donna@lmgpr.com\u00a0<\/p>\n<p>Investor relations:\u00a0<br \/>Biotricity\u00a0Investor Relations\u00a0<br \/>Investors@biotricity.com\u00a0<br \/>1.800.951.3348<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8e724213-2111-4941-8ce2-bbd6f61c312f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biotres is a compact and discreet 3 channel holter solution REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Biotricity\u00a0Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it\u00a0made\u00a0a 510(k)\u00a0submission to the U.S. Food and Drug Administration (FDA),\u00a0on December 31 2020,\u00a0for\u00a0Biotres.\u00a0The company expects this process to\u00a0take at least 4 months,\u00a0and if the\u00a0Company\u2019s 510(k) application is cleared by\u00a0the FDA\u00a0the Company expects a product launch\u00a0thereafter.\u00a0 As announced previously,\u00a0Biotres\u00a0is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues.\u00a0Biotres\u00a0can work as a Holter, Event Loop, and Extended Holter. \u201cWe are excited to announce the 510(k) FDA\u00a0submission\u00a0for\u00a0Biotres\u00a0and look forward to building out our\u00a0product offerings further in 2021,\u201d stated\u00a0Waqaas\u00a0Al Siddiq, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408386","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Biotres is a compact and discreet 3 channel holter solution REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Biotricity\u00a0Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it\u00a0made\u00a0a 510(k)\u00a0submission to the U.S. Food and Drug Administration (FDA),\u00a0on December 31 2020,\u00a0for\u00a0Biotres.\u00a0The company expects this process to\u00a0take at least 4 months,\u00a0and if the\u00a0Company\u2019s 510(k) application is cleared by\u00a0the FDA\u00a0the Company expects a product launch\u00a0thereafter.\u00a0 As announced previously,\u00a0Biotres\u00a0is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues.\u00a0Biotres\u00a0can work as a Holter, Event Loop, and Extended Holter. \u201cWe are excited to announce the 510(k) FDA\u00a0submission\u00a0for\u00a0Biotres\u00a0and look forward to building out our\u00a0product offerings further in 2021,\u201d stated\u00a0Waqaas\u00a0Al Siddiq, &hellip; Continue reading &quot;Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres\",\"datePublished\":\"2021-01-05T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/\"},\"wordCount\":825,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/\",\"name\":\"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\",\"datePublished\":\"2021-01-05T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/","og_locale":"en_US","og_type":"article","og_title":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk","og_description":"Biotres is a compact and discreet 3 channel holter solution REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Biotricity\u00a0Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it\u00a0made\u00a0a 510(k)\u00a0submission to the U.S. Food and Drug Administration (FDA),\u00a0on December 31 2020,\u00a0for\u00a0Biotres.\u00a0The company expects this process to\u00a0take at least 4 months,\u00a0and if the\u00a0Company\u2019s 510(k) application is cleared by\u00a0the FDA\u00a0the Company expects a product launch\u00a0thereafter.\u00a0 As announced previously,\u00a0Biotres\u00a0is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues.\u00a0Biotres\u00a0can work as a Holter, Event Loop, and Extended Holter. \u201cWe are excited to announce the 510(k) FDA\u00a0submission\u00a0for\u00a0Biotres\u00a0and look forward to building out our\u00a0product offerings further in 2021,\u201d stated\u00a0Waqaas\u00a0Al Siddiq, &hellip; Continue reading \"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres","datePublished":"2021-01-05T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/"},"wordCount":825,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/","name":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=","datePublished":"2021-01-05T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDcwOCMzOTA0NjM5IzIwMjg5Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biotricity-submitted-510k-u-s-fda-filing-for-biotres\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biotricity Submitted\u00a0510(k)\u00a0U.S.\u00a0FDA Filing\u00a0for\u00a0Biotres"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408386"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}